Cargando…

Raptor Preys on mTOR Imbalance in Tuberous Sclerosis

Detalles Bibliográficos
Autores principales:	Ramamurthy, Aishwarya, Carvill, Gemma Louise
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Current Literature in Basic Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273816/ https://www.ncbi.nlm.nih.gov/pubmed/37334409 http://dx.doi.org/10.1177/15357597231176235

Ejemplares similares

Double agent mTOR
por: Danzer, Steve C.
Publicado: (2019)

Tubers and Tumors Are CLIPped Together in Tuberous Sclerosis Complex
por: Dang, Louis
Publicado: (2022)

Calcium Channel Dysfunction in Epilepsy: Gain of CACNA1E
por: Carvill, Gemma L.
Publicado: (2019)

Relationship Status Update on Astrocytic VEGFR-3 and mTOR Signaling: It’s Complicated
por: Brewster, Amy L.
Publicado: (2021)

SCN8A: When Neurons Are So Excited, They Just Can’t Hide It
por: Gertler, Tracy S., et al.
Publicado: (2019)

Epilepsy Genetics: What Once Was Rare, Is Now Common
por: Calhoun, Jeffrey Dennis, et al.
Publicado: (2020)

Free as a BRD4: Bromodomain Inhibition Ameliorates Disease Phenotypes in a Model of MECP2 Deficiency and Is a Potential Therapy for Rett Syndrome
por: Lamar, Kay-Marie Joan, et al.
Publicado: (2020)

One-Hit Wonders and 2-Hit Tubers: A Second-Hit to TSC2 Causes Tuber-Like Cells in Spheroids
por: Goswami, Sonal, et al.
Publicado: (2019)

mTOR Inhibitors in Tuberous Sclerosis Complex
por: Curatolo, Paolo, et al.
Publicado: (2012)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Is mTOR inhibition a systemic treatment for tuberous sclerosis?
por: Moavero, Romina, et al.
Publicado: (2013)

Perfect match: mTOR inhibitors and tuberous sclerosis complex
por: Luo, Cong, et al.
Publicado: (2022)

A 2020 View on the Genetics of Developmental and Epileptic Encephalopathies
por: Happ, Hannah C., et al.
Publicado: (2020)

YAP enters the mTOR pathway to promote tuberous sclerosis complex
por: Liang, Ning, et al.
Publicado: (2015)

Stop the Lights—Turning Off the Electricity in Tuberous Sclerosis
por: Widdess-Walsh, Peter
Publicado: (2021)

Infantile Spasms in Tuberous Sclerosis Complex: Lesion or Network?
por: Joshi, Charuta, et al.
Publicado: (2021)

ThalaMS: New Evidence Linking Epilepsy, Multiple Sclerosis, and the Thalamus
por: Beenhakker, Mark P.
Publicado: (2022)

mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model
por: Polchi, Alice, et al.
Publicado: (2018)

mTORC2 Steals the Spotlight
por: Jansen, Laura A.
Publicado: (2020)

Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition
por: Krummel, Thierry, et al.
Publicado: (2014)

Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models
por: Magri, Laura, et al.
Publicado: (2013)

The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy
por: Goldstein, Hannah E., et al.
Publicado: (2021)

RARE-25. RETINAL ASTROCYTOMA mTOR INHIBITOR THERAPY IN TUBEROUS SCLEROSIS MOSAICISM
por: Evans, Naomi, et al.
Publicado: (2020)

Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex
por: Major, Philippe
Publicado: (2011)

Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex
por: Liang, Ning, et al.
Publicado: (2014)

Insulinoma and Tuberous Sclerosis: A Possible Mechanistic Target of Rapamycin (mTOR) Pathway Abnormality?
por: Kang, Michael Yoon, et al.
Publicado: (2017)

Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex
por: Palavra, Filipe, et al.
Publicado: (2017)

Tuberous Sclerosis Complex as Disease Model for Investigating mTOR-Related Gliopathy During Epileptogenesis
por: Zimmer, Till S., et al.
Publicado: (2020)

mTOR/Raptor signaling is critical for skeletogenesis in mice through the regulation of Runx2 expression
por: Dai, Qinggang, et al.
Publicado: (2017)

Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex
por: Karalis, Vasiliki, et al.
Publicado: (2022)

Vigabatrin Inhibits Seizures and mTOR Pathway Activation in a Mouse Model of Tuberous Sclerosis Complex
por: Zhang, Bo, et al.
Publicado: (2013)

Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC)
por: Brakemeier, Susanne, et al.
Publicado: (2017)

Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex
por: Ji, Shuang, et al.
Publicado: (2017)

Treatment of Cardiac Rhabdomyomas with mTOR Inhibitors in Children with Tuberous Sclerosis Complex—A Systematic Review
por: Sugalska, Monika, et al.
Publicado: (2021)

mTOR Inhibition: Reduced Insulin Secretion and Sensitivity in a Rat Model of Metabolic Syndrome
por: Rovira, Jordi, et al.
Publicado: (2016)

Caryospora neofalconis and other enteroparasites in raptors from Mexico
por: Santana-Sánchez, G., et al.
Publicado: (2015)

Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy
por: Wheless, James W.
Publicado: (2015)

New insights into the pathophysiology of the tuberous sclerosis complex: Crosstalk of mTOR- and hippo-YAP pathways in cell growth
por: Dill, Patricia E, et al.
Publicado: (2015)

Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
por: Li, Min, et al.
Publicado: (2019)

mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders
por: Franz, David N., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nnlqdgbl0kmnie61qnlphr2smf